MedTrace Logo

Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies

NCT04115267 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3600

Last updated 2024-06-28

No results posted yet for this study

Summary

Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed.

Conditions

  • Cancer
  • Radiotherapy Side Effect

Interventions

RADIATION

Radiotherapy

Combined modality

Sponsors & Collaborators

  • Centre hospitalier de l'Université de Montréal (CHUM)

    lead OTHER

Principal Investigators

  • Philip Wong, MD · CHUM

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-13
Primary Completion
2025-09-30
Completion
2025-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04115267 on ClinicalTrials.gov